Novo Nordisk CagriSema Outperforms Ozempic in Phase III Trial for Type 2 Diabetes and Weight Loss

Novo Nordisk's new drug CagriSema has outperformed Ozempic in a recent Phase III trial for type 2 diabetes patients, according to Clinical Trials Arena. In the REIMAGINE 2 study, CagriSema reduced HbA1c levels by 1.91 percentage points and achieved 14.2 percent weight loss after 68 weeks, compared to 1.76 percentage points and 10.2 percent with Ozempic. No weight loss plateau occurred with CagriSema, and 43 percent of patients lost at least 15 percent of their body weight. Martin Holst Lange, Novo Nordisk's executive vice president and chief scientific officer, stated that combining semaglutide and cagrilintide delivers superior blood glucose control and weight reduction.

Researchers are urging a more holistic approach to weight loss amid the Ozempic era, as reported by Medical Xpress on February 3. Experts like Martin Binks and Raedeh Basiri from George Mason University note that GLP-1 drugs such as Ozempic cause rapid weight loss but can lead to nutrient deficiencies, muscle loss, and struggles without proper nutrition, exercise, and psychological support. Many patients receive only prescriptions without multidisciplinary care, and access remains limited by cost and insurance gaps. Binks predicts broader availability with upcoming pill forms.

A study highlighted by Science Daily on January 29 warns of rapid weight regain after stopping drugs like Ozempic, with people regaining about 0.4 kilograms per month, often faster than with diet and exercise alone. Heart health and diabetes risk improvements also reverse quickly, emphasizing the need for long-term strategies beyond medication.

Oprah Winfrey has shared her experiences with GLP-1 medications, similar to Ozempic, in recent interviews covered by AOL and other outlets. At 71, she regrets not using them sooner, saying they silenced the food noise in her head and helped her view obesity as a disease, not a personal failure. She gained 20 pounds after stopping briefly but now sees these drugs as a lifelong tool, like blood pressure medication, and encourages others without shame.

These developments show evolving options and cautions in weight loss treatments. Listeners, thanks for tuning in, please subscribe, and remember, this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI